Description
EBC is currently under investigation and has not been approved by the FDA for clinical use in colorectal cancer (CRC). Its efficacy and safety profile are still being evaluated through ongoing clinical trials. It is not yet used as part of standard treatment regimens for CRC.
Mechanism of Action
EBC is an investigational drug and its mechanism of action has not been fully elucidated or approved by the FDA for clinical use.
Side Effects
Side effects are not yet fully known; ongoing clinical trials will provide more information on safety and tolerability.
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06207656
med_phase_prefix2
Recruiting
Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer
Spain